GlassScriptPhysician profile
Jeffrey Hudson
NPI 1023122942
$2,043.13
in general payments reported to CMS, 2019-2025
29 companies · $347 in 2025
The $347 reported for 2025 was more than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $336 · 2020: $94.88 · 2021: $253 · 2022: $396 · 2023: $378 · 2024: $237 · 2025: $347.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $962.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $962.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $450.31 | 2019-2023 | |
| Organon LLC | $226.17 | 2021-2025 | Jada System, Nexplanon |
| Astellas Pharma US INC | $193.30 | 2021-2025 | Veozah, Myrbetriq |
| Myriad Women'S Health, INC. | $174.90 | 2023 | Myrisk |
| Hologic Sales and Service, LLC | $168.28 | 2019-2025 | Novasure, Myosure Tissue Removal Device, Aptima |
| Mayne Pharma Commercial LLC | $95.83 | 2023-2025 | |
| Daiichi Sankyo INC. | $93.09 | 2019-2024 | Injectafer |
| Agile Therapeutics, INC. | $61.01 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $58.01 | 2019-2022 | |
| Boston Scientific Corporation | $50.70 | 2019-2021 | |
| Amgen INC. | $48.32 | 2019-2024 | Prolia, Evenity |
| Therapeuticsmd, INC. | $42.67 | 2019-2020 | |
| Exeltis, USA INC. | $41.15 | 2022-2025 | Slynd |
| Bayer Healthcare Pharmaceuticals INC. | $39.49 | 2019-2025 | |
| Sage Therapeutics, LLC | $35.27 | 2025 | Zurzuvae |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $35.27 | 2025 | Qelbree |
| Coopersurgical, INC. | $30.24 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $29.48 | 2020 | |
| Abbott Laboratories | $27.69 | 2019 | |
| Pfizer INC. | $22.86 | 2019 | |
| Millicent US INC | $17.84 | 2024 | Intrarosa, Femring |
| Sumitomo Pharma America, INC. | $16.70 | 2023 | Gemtesa |
| Pacira Pharmaceuticals Incorporated | $14.95 | 2021 | |
| Minerva Surgical, INC | $14.62 | 2024 | |
| Gilead Sciences, INC. | $13.72 | 2019 | |
| Lupin INC. | $12.18 | 2019 | |
| Allergan, INC. | $11.26 | 2019 | |
| Meditrina | $10.03 | 2023 | |
| Medela LLC | $7.79 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeffrey Hudson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.